在 20 世纪 50 年代以前，加州圣克拉拉谷不过是美国西海岸一个再普通不过的农业郊区，比起日后广为 人知的 " 硅谷 " 盛名， " 世界果篮 " 才是它当时的代名词。 转动这片土地命运齿轮的，是一系列连续登场的科技企业。从半导体到计算机，从互联网到人工智能， 每一轮技术浪潮的演进，推动硅谷完成一次又一次产业升级与城市重构。 在电子投资热潮下，诞生于硅谷的 Intel 和 AMD 相继在 1971 、 1972 年上市，大量半导体企业走入资 本市场。 这波 IPO 浪潮为硅谷的发展提供了关键资金，它资助了芯片企业的扩建和研发投入，奠定了 硅谷硬核科技的底色，也带动大量工程师、设备供应商、技术服务商向圣克拉拉谷聚集。 芯片催化了计算机产业的成熟。苹果在 1980 年的 IPO 堪称里程碑，超过 1 亿美元的募资金额，是自 1956 年福特汽车公司上市以来美国规模最大的 IPO 。从东海岸到西海岸的这次接棒，标志着全球进入 个人计算机与企业 IT 时代。 更重要的是，不断完善与迭代的创新产业链条，让硅谷吸引了一批科技极客们，他们的创意在软硬件领 域各自攻城略地，日后成长为影响无数人的世界级企业。 1982 年， ...

今天（12月25日）上午 苏州江天包装科技股份有限公司 在北京证券交易所上市 至此，苏州共有上市公司282家 境内A股227家，全国第五 科创板57家 今年以来 苏州新增境内外上市公司18家 其中境内A股上市公司10家 新增数量在全国大中城市中 位居第一 苏州亮眼的表现 同样吸引了媒体的关注 ▽ 今天（12月25日） 由新华社主办的上海证券报 刊发多版报道 《资智领航 "苏"写未来—— 从资本市场看"最强地级市"怎样炼成》 一起来看 ↓ 从"世界工厂"到全球"智造之城"，"最强地级市"苏州，正奋力实现产业体系与城市能级的双跃升。 数据显示，2025年前三季度，苏州以19930.21亿元的地区生产总值和5.5%的增速，持续领跑全国地级市。其中，工业增加值对经济增长的贡献率达 50.9%。 "十四五"期间，苏州深入推进新型工业化，全面实施"苏州智造"强基提质工程，加快构建由10个重点产业集群和30条重点产业链组成的"1030"现代产业体 系。目前，苏州已形成电子信息、高端装备、新材料3个万亿级产业，11个千亿级产业，6个国家先进制造业集群，较上一个五年实现跨越式增长。 产业报国"种子" 激励企业敢为人先 "全球首 ...

证券日报网讯12月19日，国投丰乐（000713）在互动平台回答投资者提问时表示，国投种业目前重点从 生物技术、资本支持、资源整合、科研人才等方面对公司种业进行赋能。 ...

Core Insights - The article highlights the significant breakthroughs achieved by innovative pharmaceutical companies listed on the STAR Market, particularly in the context of the 2025 World Lung Cancer Conference, where several companies presented important research findings [1][2]. Group 1: Innovative Drug Approvals - As of now, nine domestic innovative drugs have received FDA approval in the U.S., with four of these coming from STAR Market companies, including BeiGene, Junshi Biosciences, and Dizal Pharmaceuticals [1]. - The STAR Market's registration system is seen as a key factor in identifying high-quality innovative drug companies, with a call for greater tolerance for the volatility exhibited by these firms [1][2]. Group 2: Investment and R&D Growth - Bai Li Tianheng's R&D investment increased from 181 million yuan to 375 million yuan between 2019 and 2022, with R&D expenses rising from 15% to 53% of revenue [3]. - The company successfully went public on the STAR Market in January 2023, benefiting from the market's inclusive listing standards that allow unprofitable companies to list [3][4]. Group 3: Financial Performance and Market Position - Bai Li Tianheng's strategic partnership with Bristol-Myers Squibb for its drug BL-B01D1 resulted in a total transaction value of 8.4 billion USD, marking a record for domestic innovative drug business development [7]. - The company's market capitalization exceeded 100 billion yuan, making it one of the youngest innovative drug companies in the A-share market [8]. Group 4: Clinical Trials and Drug Development - Bai Li Tianheng has over 80 clinical trials ongoing globally for its 15 candidate drugs, with a projected funding gap of 4.819 billion yuan over the next three years [9]. - The company reported a 90.74% year-on-year increase in R&D investment in the first half of 2024, reaching 1.043 billion yuan [8]. Group 5: Capital Market Dynamics - The STAR Market's efficient capital formation mechanism supports drug companies at various stages of development, facilitating a cycle of investment, cultivation, listing, exit, and reinvestment [13]. - The recent regulatory changes have expedited the refinancing process for STAR Market companies, allowing Bai Li Tianheng to raise up to 3.9 billion yuan for R&D projects in a short timeframe [12].

Group 1 - The core viewpoint emphasizes that unicorn and gazelle companies are not only key players in technological innovation but also crucial for leading the development of emerging industries and nurturing new growth drivers [1] - Recent initiatives from regions like Shanghai and Sichuan focus on supporting unicorn and gazelle companies through financial support, talent acquisition, and open scenarios [1] - According to the "World Unicorn Company Development Report 2025," nearly 30% of global unicorn companies are based in China, with 53 new unicorns emerging in 2024, primarily in hard technology sectors such as artificial intelligence, integrated circuits, and clean energy [1] Group 2 - To enhance policy precision, a tiered cultivation mechanism should be established, dynamically selecting high-potential companies based on local characteristics and providing targeted support for different stages of growth [2] - Financial capital is essential for the rapid growth and innovation of unicorn and gazelle companies, necessitating the establishment of long-term mechanisms and optimized financial resource supply to meet diverse financing needs [3] - Creating a supportive innovation ecosystem is vital, encouraging collaboration between leading companies and potential unicorns, integrating resources, and facilitating the transformation of research outcomes into market applications [4]